9. 产品管线-iPSC分化功能细胞

9. Celzyva产品管线：iPSC分化人功能细胞  Celzyva Product Pipeline: iPSC-derived Human Functional Cells

源于日本京都大学山中伸弥教授获2012年诺贝尔奖的技术发明，诱导多能干细胞（iPSC）分化来源的各种功能细胞，已成为细胞治疗领域中技术门槛最高、最具前景和想象空间的一类药物。其中，iPSC分化的神经前体细胞(NPC)、少突胶质前体细胞(OPC)、胰岛β细胞等，正为众多尚未满足临床需求的重大疾病带来治疗希望。

Originating from the technological breakthrough pioneered by Professor Shinya Yamanaka—for which he was awarded the 2012 Nobel Prize—the differentiation of induced pluripotent stem cells (iPSCs) into various functional cell types represents one of the most promising and visionary classes of cell-based therapeutics. Characterized by high technical barriers, this field holds immense potential. Specifically, iPSC-derived neural precursor cells (NPCs), oligodendrocyte precursor cells (OPCs), and beta cells, among others, are emerging as beacons of hope for addressing a range of serious diseases with significant unmet medical needs.

9.1. Celzyva获得日本京都大学GMP级诱导多能干细胞(iPSC)主库 Celzyva Licenses a GMP-Grade iPSC Master Cell Bank from Kyoto University, Japan

........

9.2. Celzyva诱导多能干细胞(iPSC)分化人功能细胞产品总览与管线图 Overview & Pipeline Diagram of Celzyva iPSC-derived Human Functional Cell Products

9.3. 已完成临床前研发并已获批IND的、处于I/II期临床试验阶段的人多能干细胞分化功能细胞产品管线 IND-approved, Phase I/II clinical-stage Human iPSC-derived Functional Cell Product Pipeline

9.3.1. ACT121细胞注射液治疗缺血性脑卒中偏瘫后遗症 ACT121 cell intravenous injection to treat post-ischemic stroke Sequelae hemiplegia

Click to access the dedicated information page for this Cell Therapy Product.

9.4. 预计1年内可完成临床前研发并获批IND的人多能干细胞分化功能细胞产品管线 iPSC-derived Functional Cell Product Pipeline Targeting Completion of Preclinical Studies and IND Approvals within 1 year

9.4.1. ACT131细胞注射液治疗脊髓损伤 ACT131 cell injection to treat spinal cord injury (SCI)

Click to access the dedicated information page for this Cell Therapy Product.

9.5. 处于临床前研发的人多能干细胞分化功能细胞产品管线 Preclinical-Study Stage Human iPSC-derived Functional Cell Product Pipeline

9.5.1. aCGT iNK/CAR-iNK注射液治疗急性髓系白血病 aCGT iNK/CAR-iNK Injection for the Treatment of Acute Myeloid Leukemia (AML)

Click to access the dedicated information page for this Cell Therapy Product.

9.5.2. aCGT异体iPSC源视网膜色素上皮细胞注射液治疗年龄相关性黄斑变性 aCGT Allogeneic iPSC derived retinal pigment epithelial (RPE) cells injection to treat Age-Related Macular Degeneration (AMD)

Click to access the dedicated information page for this Cell Therapy Product.

9.5.3. aCGT异体iPSC源胰岛细胞注射液治疗1型糖尿病 aCGT Allogeneic iPSC derived Pancreatic islet cell injection to treat type 1 diabetes mellitus (T1DM)

Click to access the dedicated information page for this Cell Therapy Product.

9.5.4. aCGT双靶点CAR-iNK治疗非小细胞肺癌 aCGT Dual-targeted CAR-iNK for the treatment of non-small cell lung cancer (NSCLC)

Click to access the dedicated information page for this Cell Therapy Product.

9.5.5. aCGT双靶点CAR-iNK治疗系统性红斑狼疮 aCGT Dual-target CAR-iNK therapy for systemic lupus erythematosus (SLE)

Click to access the dedicated information page for this Cell Therapy Product.

9.5.6. aCGT异体功能增强少突胶质前体细胞注射液治疗脊髓损伤 aCGT Allogeneic Functional Enhancement of Oligodendrocyte Progenitor Cells (OPC) Injection for Treating Spinal Cord Injury (TSCI)

Click to access the dedicated information page for this Cell Therapy Product.

9.5.7. aCGT基因编辑的造血干细胞治疗β地中海贫血 aCGT Gene-edited hematopoietic stem cell therapy for beta-thalassemia

Click to access the dedicated information page for this Cell Therapy Product.